Caribou Biosciences, Inc. Revenues
Caribou Biosciences, Inc. (CRBU) reported Revenues of $0 for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-09-02.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2021-09-02
- Caribou Biosciences, Inc. revenues for the quarter ending 2021-06-30 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month |
|---|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-09-02 | $0.00 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |